Article
Medicine, Research & Experimental
Yujeong Moon, Man Kyu Shim, Jiwoong Choi, Suah Yang, Jinseong Kim, Wan Su Yun, Hanhee Cho, Jung Yeon Park, Yongju Kim, Joon-Kyung Seong, Kwangmeyung Kim
Summary: In this study, the researchers propose a new strategy to enhance cancer immunotherapy by using anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs). The PD-NPs are taken up by cancer cells and release the drug, resulting in the disruption of immune-suppressing pathways and the enhancement of T lymphocyte immune responses. The results show that PD-NPs accumulate in tumor tissues and recruit a large amount of immune cells, leading to effective antitumor effects. This strategy has the potential to overcome the toxicity and low response rate issues in current cancer immunotherapy.
Article
Oncology
Liang Mao, Yao Xiao, Qi-Chao Yang, Shao-Chen Yang, Lei-Lei Yang, Zhi-Jun Sun
Summary: This study found that CD155 and PD-L1 are highly co-expressed on MDSCs in HNSCC patients, and the combined blockade of TIGIT/CD155 and PD-1/PD-L1 signaling significantly inhibited tumor growth in mouse models, enhanced the percentage of effector T cells, and induced immune memory effects.
Review
Chemistry, Medicinal
Qi Zhang, Chenying Yang, Xingsu Gao, Ju Dong, Caiyun Zhong
Summary: This article discusses the role of immune checkpoint blockade in cancer treatment and explores the modulation of immune checkpoint proteins by phytochemicals and their combination effects with immune checkpoint inhibitors in various malignancies.
PHYTOTHERAPY RESEARCH
(2023)
Article
Medicine, General & Internal
Julika Ribbat-Idel, Franz F. Dressler, Rosemarie Krupar, Christian Watermann, Finn-Ole Paulsen, Patrick Kuppler, Luise Klapper, Anne Offermann, Barbara Wollenberg, Dirk Rades, Simon Laban, Markus Reischl, Karl-Ludwig Bruchhage, Christian Idel, Sven Perner
Summary: This study tested five different PD-L1 clones on primary HNSCC tumor tissue of 75 patients and found that the percentages of positive immune and tumor cells varied greatly. The choice of antibody strongly influenced the resulting combined positive score and eligibility for checkpoint inhibitor regimens. The study highlights the importance of determining PD-L1 expression for therapeutic decision making and suggests that back-to-back testing of different PD-L1 clones may be beneficial.
FRONTIERS IN MEDICINE
(2021)
Article
Chemistry, Multidisciplinary
Jingmei Pan, Xilin Li, Binfen Shao, Funeng Xu, Xuehui Huang, Xing Guo, Shaobing Zhou
Summary: A nanocarrier that achieves self-blockade of PD-L1 in tumor cells and a detection kit to quantitatively measure the binding rate of PD-1/PD-L1 have been developed, improving the efficacy of PD-1/PD-L1 self-blocking therapy.
ADVANCED MATERIALS
(2022)
Review
Immunology
Meng Chen, Chenyan Li, Mingjun Sun, Yiling Li, Xuren Sun
Summary: This review summarizes the challenges in the treatment of gastroesophageal cancers (GECs) and the use of immune checkpoint inhibitors as a new therapeutic approach. Ongoing clinical trials with PD-1/PD-L1 pathway blockers in GEC are discussed, and further research is needed to apply them in the clinical care of patients. The review provides insights into the efficacy of PD-1/PD-L1 antibodies as a first-line treatment and in second-line or more treatment for GEC.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Kimberly M. Burcher, Jeffrey W. Lantz, Elena Gavrila, Arianne Abreu, Jack T. Burcher, Andrew T. Faucheux, Amy Xie, Clayton Jackson, Alexander H. Song, Ryan T. Hughes, Thomas Lycan, Paul M. Bunch, Cristina M. Furdui, Umit Topaloglu, Ralph T. B. D'Agostino, Wei Zhang, Mercedes Porosnicu
Summary: This study evaluated tumor mutational burden and programmed death ligand-1 measurements in relation to demographics, outcomes, and response to immunotherapy in head and neck squamous cell carcinoma. The results aim to lay the groundwork for predicting individual responses to immune checkpoint inhibitors.
Article
Otorhinolaryngology
Shuang Huang, Chuang Xiong, Kui Tan
Summary: Head and neck squamous cell carcinoma (HNSCC) is a common cancer with a high percentage of patients diagnosed at a locally advanced stage. Traditional neoadjuvant strategies for HNSCC have limited efficacy and complications, necessitating the exploration of new approaches. The breakthrough progress of PD-1/PD-L1 axis blockade in recurrent/metastatic HNSCC has shown promise for neoadjuvant therapy. This study found that the combination of PD-1/PD-L1 axis blockade and chemotherapy or radiotherapy had high response rates and achieved complete or partial pathological responses. The combination of PD-1/PD-L1 axis blockade and CTLA-4 blockade requires further investigation. Pathological complete response and main pathological response can serve as early indicators for long-term prognosis.
AMERICAN JOURNAL OF OTOLARYNGOLOGY
(2023)
Review
Pharmacology & Pharmacy
Zikun Peng, Ming Li, Huayi Li, Qinglei Gao
Summary: Immune checkpoint inhibitors (ICIs) have revolutionized treatment in oncology, but have shown modest efficacy in ovarian cancer. This review summarizes clinical trials of PD-1/PD-L1 blockade in ovarian cancer, categorizes resistance mechanisms, and introduces candidate approaches to enhance the efficacy of anti-PD-1/PD-L1 antibodies by rewiring the tumor microenvironment (TME).
DRUG DISCOVERY TODAY
(2023)
Article
Oncology
Jiawei Tang, Junhui Tang, Hui Li, Jing Zhou, Najiao Tang, Qiong Zhu, Xinxin Wang, Bo Zhu, Ningshan Li, Zheng Liu
Summary: In this study, an improved ultrasonic horn device, Ultrasound Needle (UN), was used to induce anti-tumor immune responses. The mechanical destruction and thermal ablation effects of UN treatment increased the infiltration of CD8(+) T cells in tumors, relieved the immunosuppressive tumor microenvironment, and enhanced the therapeutic efficacy of the anti-PD-L1 antibody.
Review
Biochemistry & Molecular Biology
David Escors, Ana Bocanegra, Luisa Chocarro, Ester Blanco, Sergio Pineiro-Hermida, Maider Garnica, Leticia Fernandez-Rubio, Ruth Vera, Hugo Arasanz, Grazyna Kochan
Summary: PD-L1/PD-1 blockade immunotherapy has revolutionized cancer treatment, but its mechanisms and effectiveness are still not fully understood. This article reviews the evidence supporting the role of CD4 T cells in anti-tumor immunity and their potential as predictors of response to PD-L1/PD-1 blockade immunotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Tian Tian, Zhaoming Li
Summary: Blocking therapy targeting programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) has revolutionized the treatment of malignant tumors, but patient response rates are low and drug resistance is a major concern. Combining this therapy with Tim-3 blockade may offer a promising approach to overcoming resistance in cancer immunotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Mengwen Huang, Songrong Wang, Senbiao Chen, Jilong Wang, Congfei Xu, Jing Liu, Zhexiong Lian, Xiaojiao Du, Jun Wang
Summary: In this study, the effects of pegylated liposomal mitoxantrone (PL-MIT) on tumor immune landscape were investigated. PL-MIT was found to enhance multiple damage-associated molecule patterns (DAMPs) signals in tumors, promote dendritic cells maturation and T cells infiltration, and induce high expression of PD-L1 on myeloid-derived suppressor cells (MDSC), which negatively impacts antitumor immunity.
Article
Pharmacology & Pharmacy
Wenxin Zhang, Xiaohui Pan, Yanjun Xu, Hongjie Guo, Mingming Zheng, Xi Chen, Honghai Wu, Fengming Luan, Qiaojun He, Ling Ding, Bo Yang
Summary: Mevalonate metabolism plays an important role in regulating tumor growth and progression. This study found that high plasma mevalonate levels positively correlated with better response to anti-PD-(L)1 therapy in NSCLC patients. Mevalonate supplementation up-regulated the expression of PD-L1 and improved CD274 mRNA stability, which enhanced the anti-tumor effect of anti-PD-L1 and improved T cell function.
ACTA PHARMACEUTICA SINICA B
(2023)
Review
Immunology
Andrea Botticelli, Alessio Cirillo, Lidia Strigari, Filippo Valentini, Bruna Cerbelli, Simone Scagnoli, Edoardo Cerbelli, Ilaria Grazia Zizzari, Carlo Della Rocca, Giulia D'Amati, Antonella Polimeni, Marianna Nuti, Marco Carlo Merlano, Silvia Mezi, Paolo Marchetti
Summary: This study compared the efficacy of anti-PD-1 and anti-PD-L1-based therapy in R/M HNSCC patients through a systematic review and network meta-analysis. It found no significant differences in overall survival between different subgroups, except for metastatic patients where anti-PD-1-based therapy was associated with significantly less risk of death.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Medicine, Research & Experimental
Christopher A. Maroun, Gangcai Zhu, Carole Fakhry, Christine G. Gourin, Tanguy Y. Seiwert, Peter S. Vosler, Marietta Tan, Wayne Koch, David W. Eisele, Drew M. Pardoll, Rajarsi Mandal
Summary: Young patients with OCSCC aged 45 years and younger exhibit an attenuated immune response, potentially due to a lower frequency of immunogenic mutations. This finding may contribute to the pathogenesis of these tumors and aid in informing personalized immune-based therapeutic strategies for young patients with OCSCC.
Article
Multidisciplinary Sciences
Zhexuan Li, Changhan Chen, Juncheng Wang, Ming Wei, Guancheng Liu, Yuexiang Qin, Li She, Yong Liu, Donghai Huang, Yongquan Tian, Gangcai Zhu, Xin Zhang
Summary: The study revealed a significant elevation of PLAU mRNA in HNSCC tumor samples and a decrease in methylation levels compared to normal specimens. PLAU could serve as an independent indicator for HNSCC prognosis, with associations to neck node status, potentially becoming a biomarker for predicting outcomes of HNSCC patients.
Article
Oncology
Gang Chen, Zhexuan Li, Changhan Chen, Jiajia Liu, Weiming Zhu, Li She, Huimei Huang, Yuexiang Qin, Guancheng Liu, Juncheng Wang, Yong Liu, Donghai Huang, Qinglai Tang, Xin Zhang, Gangcai Zhu
Summary: PRAS40 serves a critical role in HNSCC with high expression as a favorable prognostic factor. Knockout of PRAS40 promotes colony formation, cell migration, and invasion in HNSCC cells, while the underlying mechanisms and altered pathways were investigated. High PRAS40 expression in HNSCC patients correlates with specific molecular pathways and immune cell infiltrations, suggesting its potential as a prognostic predictor and therapeutic target.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Bin Tang, Gangcai Zhu, Changhan Chen, Siyuan Zheng, Yuting Pu, Yimin Xu, Huimei Huang, Gang Wang, Donghai Huang, Yong Liu, Xin Zhang
Summary: The presence of HCV RNA transcript is independently associated with a favorable prognosis in non-HPV associated HNSCC, correlating with clinical pathological stages and survival outcomes, as well as influencing the abundance of immune cells.
Review
Immunology
Yuting Pu, Gangcai Zhu, Yimin Xu, Siyuan Zheng, Bin Tang, Huimei Huang, Irene X. Y. Wu, Donghai Huang, Yong Liu, Xin Zhang
Summary: The systematic review found that elevated activities of vitamin D by diet intake, genomic polymorphisms, or circulated 25-OHD may protect people from HNC and improve the prognosis of patients with HNC.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Surgery
Xingyu Zhang, Gangcai Zhu, Bin Tang, Huimei Huang, Changhan Chen, Siyuan Zheng, Yuting Pu, Yimin Xu, Gang Wang, Donghai Huang, Yong Liu, Xin Zhang
Summary: The study found that age, EOD, T stage, N stage, and treatment may correlate with overall survival and disease-specific survival in patients with PSCCTh. The established prediction model can assist physicians in evaluating patients' prognoses and providing precise therapy for PSCCTh.
Article
Immunology
Juncheng Wang, Yuxi Tian, Gangcai Zhu, Zhexuan Li, Zhisheng Wu, Guifang Wei, Liming Zhuang, Zhonghua Li, Xun Chen, Xin Zhang, Jinyang Zheng, Gengming Cai
Summary: This study aimed to quantify the Immune, Stromal, and ESTIMATE scores based on the gene matrix of HNSCC patients from The Cancer Genome Atlas (TCGA). Using weighted gene co-expression network (WGCNA) and protein-protein interaction (PPI) analyses, 17 hub gene signatures were selected from the key gene module mostly correlated to immunocyte infiltration. High expression of certain genes was associated with a good prognosis in patients with HNSCC.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Immunology
Huimei Huang, Shisheng Li, Qinglai Tang, Gangcai Zhu
Summary: Nasopharyngeal carcinoma (NPC) is a malignant tumor characterized by geographic distribution and EBV infection. Metabolic reprogramming in NPC cells may facilitate cancer progression and immunosuppression through cell-cell communications with surrounding immune cells. This review discusses dysregulated metabolism processes in NPC and the potential connections between reprogrammed metabolism, tumor immunity, and therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Otorhinolaryngology
Neha Amin, Christopher A. Maroun, Margueritta El Asmar, Hosam H. Alkhatib, Meytal Guller, Matthew E. Herberg, Gangcai Zhu, Tanguy Y. Seiwert, Drew Pardoll, David W. Eisele, Carole Fakhry, Christine G. Gourin, Rajarsi Mandal
Summary: This systematic review provides a comprehensive summary of neoadjuvant head and neck cancer immunotherapy clinical trials focusing on PD-1/PD-L1 axis blockade. Results show promising efficacy of neoadjuvant immunotherapy with favorable response rates and no unexpected immune-related toxicities in phase I/II trials.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2022)
Article
Oncology
Juncheng Wang, Yuxi Tian, Huimei Huang, Donghai Huang, Yong Liu, Yongquan Tian, Gangcai Zhu, Xin Zhang, Robert L. Ferris
Summary: This study investigated the association between HPV status and survival in metastatic pharyngeal HNSCC patients. The results showed that HPV-positive mHNSC-P patients had better overall survival and disease-specific survival compared to HPV-negative patients. Subgroup analysis revealed that HPV positivity conferred survival benefits in patients with oligometastasis among metastatic oropharyngeal cancer patients.
Article
Otorhinolaryngology
Gangcai Zhu, Neha Amin, Matthew E. Herberg, Christopher A. Maroun, Hao Wang, Meytal Guller, Christine G. Gourin, Lisa M. Rooper, Peter S. Vosler, Marietta Tan, Gypsyamber D'Souza, Wayne M. Koch, David W. Eisele, Tanguy Y. Seiwert, Carole Fakhry, Drew M. Pardoll, Rajarsi Mandal
Summary: In this study, HPV-positive status was associated with improved survival in OPSCC patients but not in non-OP HNSCC or CESC patients. HPV-positive OPSCCs showed higher tumor immune infiltration and immunomodulatory receptor expression compared to HPV-negative OPSCCs.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2022)
Article
Oncology
Meytal Guller, Matthew Herberg, Neha Amin, Hosam Alkhatib, Christopher Maroun, Evan Wu, Hailey Allen, Ying Zheng, Christine Gourin, Peter Vosler, Marietta Tan, Wayne Koch, David Eisele, Tanguy Seiwert, Carole Fakhry, Drew Pardoll, Gangcai Zhu, Rajarsi Mandal
Summary: The study investigated the impact of nutritional status on immunotherapy response in head and neck cancer patients, finding that poor nutritional status is associated with negative post-immunotherapy outcomes.
Article
Multidisciplinary Sciences
Fen Zhang, Huimei Huang, Yuexiang Qin, Changhan Chen, Li She, Juncheng Wang, Donghai Huang, Qinglai Tang, Yong Liu, Gangcai Zhu, Xin Zhang
Summary: Elevated MTDH expression is associated with worse overall survival and poorer immune response in cancer patients, potentially by impacting tumor-infiltrating immune cells and inhibitory immune checkpoint expression. The interactions between epithelial-to-mesenchymal transition, m6A-RNA methylation, and MTDH may elucidate the mechanisms of MTDH resistance to immune checkpoint blockade treatment. Targeting MTDH may help overcome immunotherapy resistance in a wide range of cancers, although further experiments and trials are needed in the future.
Article
Otorhinolaryngology
Hosam H. Alkhatib, Christopher A. Maroun, Neha Amin, Gangcai Zhu, Meytal Guller, Matthew E. Herberg, Evan S. Wu, Tanguy Y. Seiwert, Lisa M. Rooper, David W. Eisele, Carole Fakhry, Drew Pardoll, Rajarsi Mandal
Summary: This retrospective cohort study found that tumor grade is associated with immunotherapy response in patients with recurrent or metastatic mucosal HNSCC, with higher grade tumors showing a higher clinically beneficial response to immunotherapy.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2022)
